Viking Therapeutics

$6.41
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.10 (+1.60%) Today
+$0.05 (+0.79%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell VKTX and other stocks, options, and ETFs commission-free!

About VKTX

Viking Therapeutics, Inc. Common Stock, also called Viking Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA. The listed name for VKTX is Viking Therapeutics, Inc. Common Stock.

CEO
Brian Lian
Employees
19
Headquarters
San Diego, California
Founded
2012
Market Cap
463.97M
Price-Earnings Ratio
Dividend Yield
Average Volume
1.21M
High Today
$6.43
Low Today
$6.25
Open Price
$6.26
Volume
1.02M
52 Week High
$8.87
52 Week Low
$3.26

Collections

VKTX Earnings

-$0.15
-$0.10
-$0.05
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 24, After Hours

You May Also Like